Centogene NV rises on expansion of agreement with Pfizer

Crown LiquidationCo NV in liquidatie

17/03/2022 17:30

** U.S.-listed shares of Germany-based diagnostic and pharma
co  CNTG.O  rise 10.8% to $4.18
    ** Co expands its data access and collaboration agreement
with Pfizer Inc  PFE.N   urn:newsml:reuters.com:*:nGNX3jNlfq
    ** Initial agreement, which granted Pfizer access to data of
interest from Centogene's Bio/Databank, was signed in 2019
    ** New collaborative research project aims to substantiate
earlier results and further leverage CNTG's Bio/Databank to
evaluate rare genetic causes of neurodegenerative diseases
    ** The Bio/Databank integrates patient-consented data,
including clinical information, health records, genetic
insights, biomarkers and patient recorded outcomes
    ** U.S.-listed stock has lost ~20% YTD, including session
moves

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))